Asthma Market is projected to grow at a CAGR of 1.9% During 2024-2034, Estimates DelveInsight

DelveInsight's "Asthma Market Insights, Epidemiology, and Market Forecast - 2034" report offers a comprehensive analysis of asthma, including historical and projected epidemiology, along with market trends across the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.

Explore detailed insights into the evolving Asthma Market here: Asthma Market Size - https://www.delveinsight.com/report-store/asthma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Highlights from the Asthma Market Report
• February 2025 - Areteia Therapeutics: Ongoing study evaluating the efficacy and safety of dexpramipexole as an oral add-on therapy for patients with uncontrolled eosinophilic asthma and a history of exacerbations.
• February 2025 - AstraZeneca: Phase II trial examining the safety and therapeutic performance of inhaled PT007 (AS MDI) versus placebo and Ventolin Evohaler in adults aged 18-65 with asthma.
• Approximately 55 million diagnosed prevalent asthma cases were reported across the 7MM, with prevalence expected to rise through 2034.
• The US accounted for ~26 million diagnosed cases, projected to increase by 2034.
• In the US, an estimated 4.8 million pediatric and 21.2 million adult asthma cases were recorded in 2023.
• Within EU4+UK, the UK reported the highest burden (8.4 million cases), followed by Germany (4.9 million) and France (4.7 million).
• Intermittent asthma was the most common severity segment in EU4+UK, with Germany alone reporting ~1.7 million intermittent cases.
• In Japan, type-2 inflammation asthma was most prevalent (175,000 cases in 2023), compared with 39,000 non-type-2 cases.
• Female patients accounted for ~2.6 million diagnosed cases in Japan compared to 1.7 million in males.
• Leading asthma companies include GSK, Teva, Launch Therapeutics, AB Science, AstraZeneca, Areteia Therapeutics, Knopp Biosciences, Palobiofarma, Pivotal S.L., Sterna Biologicals, Sanofi, Connect Biopharma, and others.
vProminent marketed and pipeline therapies include NEXThaler 100/6 mcg DPI, FOSTER, Seretide, and GW815SF (Salmeterol/Fluticasone propionate HFA MDI).

Gain strategic insights into the Asthma Therapeutics Landscape: Asthma Market Outlook - https://www.delveinsight.com/report-store/asthma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Asthma Epidemiology Segmentation (7MM)
• Total diagnosed prevalent cases
• Age-specific distribution
• Gender-specific distribution
• Severity-based segmentation
• Type-specific severity segmentation

Download the report for a full breakdown of epidemiological drivers: Asthma Prevalence - https://www.delveinsight.com/report-store/asthma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Marketed Asthma Therapies
• AIRSUPRA (albuterol and budesonide) - AstraZeneca/Avillion
AIRSUPRA is a first-of-its-kind FDA-approved rescue inhaler combining a bronchodilator (albuterol) and an anti-inflammatory corticosteroid (budesonide) via Aerosphere technology. Approved in 2023 and available since 2024, it provides on-demand relief by preventing bronchoconstriction and lowering exacerbation risk. Its development traces back to AstraZeneca's acquisition of Pearl Therapeutics and subsequent partnership with Avillion.

• TEZSPIRE (tezepelumab) - Amgen/AstraZeneca
TEZSPIRE is a monoclonal antibody targeting TSLP, a central upstream driver of asthma inflammation. Effective across biomarker profiles, it is approved in the US, EU, and Japan for severe asthma (≥12 years). Given subcutaneously every four weeks, TEZSPIRE has earned Breakthrough Designation, Priority Review, and approvals for self-administration.

• CINQAIR/CINQAERO (reslizumab) - Teva Pharmaceuticals
Reslizumab, an IL-5 antagonist for severe eosinophilic asthma, is administered intravenously (3 mg/kg every 4 weeks). Approved in 2016, it reduces eosinophilic inflammation and exacerbations. It is marketed as CINQAIR in the US and CINQAERO in Europe.

Emerging Asthma Therapies
• Depemokimab (GSK3511294) - GSK
A next-generation IL-5 monoclonal antibody engineered for enhanced affinity and long-term suppression of eosinophil-driven inflammation. It is the first biologic designed for once-every-26-weeks subcutaneous dosing.

• Masitinib - AB Science
An investigational oral tyrosine kinase inhibitor targeting mast cell activation pathways involved in bronchoconstriction, airway remodeling, and inflammation. Phase III trials for severe persistent asthma were completed in 2020.

• BREZTRI AEROSPHERE (PT010) - AstraZeneca/Amgen
A triple fixed-dose inhaler combining budesonide (ICS), glycopyrronium (LAMA), and formoterol (LABA), delivered through Aerosphere pMDI technology. Each component provides complementary anti-inflammatory or bronchodilatory effects.

Learn more about evolving treatment paradigms: Asthma Treatment Market - https://www.delveinsight.com/sample-request/asthma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Asthma Treatment Landscape
Asthma management focuses on symptom control and risk reduction rather than cure. Current therapies fall into:
• Anti-inflammatory agents: ICS, leukotriene modifiers, mast cell stabilizers
• Bronchodilators: beta-agonists, anticholinergics, methylxanthines
• Combination inhalers and targeted biologics are used particularly for severe eosinophilic asthma.

Asthma Market Outlook
Asthma remains a significant global health burden characterized by episodic or persistent symptoms and airflow limitation. Treatment goals include symptom minimization, activity maintenance, and prevention of long-term complications. Guideline-driven therapy selection is based on disease severity, risk profile, and treatment response.

Explore in-depth strategic insights and market dynamics: Asthma Market Drivers and Barriers - https://www.delveinsight.com/sample-request/asthma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Asthma Market Report Scope
• Geographic Coverage: 7MM
• Companies: GSK, Teva, Launch Therapeutics, AB Science, AstraZeneca, Areteia Therapeutics, Knopp Biosciences, Palobiofarma, Pivotal S.L., Sterna Biologicals, Sanofi, Connect Biopharma, etc.
• Therapies Covered: NEXThaler, FOSTER, Seretide, GW815SF, among others
• Market access, reimbursement, unmet needs, drivers and barriers, emerging therapies

Table of Contents
1. Key Insights
2. Report Introduction
3. Market Overview at a Glance
4. Epidemiology and Market Forecast Methodology
5. Executive Summary
6. Key Events
7. Disease Background and Overview
8. Asthma Patient Journey
9. Asthma Epidemiology and Patient Population
10. Asthma Marketed Drugs
11. Emerging Asthma Drugs
12. Asthma: Market Analysis
14. Key Opinion Leaders' Views
15. SWOT Analysis
16. Asthma Unmet Needs
17. Market Access and Reimbursement
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.